Near‐Infrared Responsive PEGylated Gold Nanorod and Doxorubicin Loaded Dissolvable Hyaluronic Acid Microneedles for Human Epidermoid Cancer Therapy (Adv. Therap. 2/2018). Issue 2 (25th June 2018)

• Record Type: Journal Article
• Authors: Hao, Ying; Chen, YuWen; Lei, MinYi; Zhang, TaoYe; Cao, YiPing; Peng, JinRong; Chen, LiJuan; Qian, ZhiYong
• Is Part Of: Advanced therapeutics. Volume 1:Issue 2(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-06-25
• Subjects: Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.201870004
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract : Human Epidermoid Cancer In article no.1800008, ZhiYong Qian and co‐workers develop a near‐infrared (NIR) responsive PEGylated gold nanorod (GNR‐PEG) and doxorubicin (DOX) loaded dissolvable hyaluronic acid (HA) microneedle (GNR‐PEG&DOX@HA MN) for human epidermoid cancer therapy. The GNR‐PEG&DOX@HA MNs have good skin penetration capability and the release behavior of the DOX from GNR‐PEG&DOX@HA MNs can be controlled by near infra‐red light. An in vivo antitumor study, shows that transcutaneously delivered GNR‐PEG&DOX@HA MNs demonstrates remarkable antitumor efficacy, such that all treated mice were cured without recurrence after only one treatment.